Electromed, Inc. ELMD
We take great care to ensure that the data presented and summarized in this overview for Electromed, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELMD
View all-
Vanguard Group Inc Valley Forge, PA436KShares$11 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny217KShares$5.46 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA196KShares$4.93 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX190KShares$4.78 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA189KShares$4.76 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN176KShares$4.41 Million0.27% of portfolio
-
Mario Gabelli Gamco Investors, Inc. Et Al | Rye, Ny142KShares$3.57 Million0.04% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny140KShares$3.52 Million0.01% of portfolio
-
Hunter Associates Investment Management LLC Pittsburgh, PA118KShares$2.96 Million0.4% of portfolio
-
Two Sigma Investments, LP New York, NY110KShares$2.76 Million0.0% of portfolio
Latest Institutional Activity in ELMD
Top Purchases
Top Sells
About ELMD
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care and institutional markets for patients with bronchiectasis, cystic fibrosis, and neuromuscular diseases. It markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Insider Transactions at ELMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2025
|
Kathleen A Tune Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.67%
|
-
|
|
Dec 01
2025
|
Kathleen Skarvan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+7.77%
|
-
|
|
Dec 01
2025
|
Joseph L. Galatowitsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.67%
|
-
|
|
Dec 01
2025
|
Gregory Fluet Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+12.5%
|
-
|
|
Dec 01
2025
|
Stan K. Erickson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+7.17%
|
-
|
|
Dec 01
2025
|
Andrew Summers Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+20.0%
|
-
|
|
Dec 01
2025
|
Andrea M. Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+14.29%
|
-
|
|
Sep 11
2025
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
3,153
-100.0%
|
$75,672
$24.42 P/Share
|
|
Sep 10
2025
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
62,561
-49.43%
|
$1,564,025
$25.35 P/Share
|
|
Sep 02
2025
|
Bradley M. Nagel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,300
+19.53%
|
-
|
|
Sep 02
2025
|
Bradley M. Nagel Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
562
-3.29%
|
$12,926
$23.95 P/Share
|
|
Sep 02
2025
|
James L. Cunniff CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+10.32%
|
-
|
|
Sep 02
2025
|
James L. Cunniff CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,291
-0.98%
|
$29,693
$23.95 P/Share
|
|
Feb 24
2025
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
50,751
-43.58%
|
$1,370,277
$27.3 P/Share
|
|
Feb 21
2025
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
25,451
-3.6%
|
$712,628
$28.58 P/Share
|
|
Feb 20
2025
|
Andrew Summers Director |
SELL
Open market or private sale
|
Indirect |
35,273
-4.52%
|
$1,022,917
$29.26 P/Share
|
|
Feb 18
2025
|
Kathleen Skarvan Director |
SELL
Open market or private sale
|
Direct |
38,954
-54.42%
|
$1,129,666
$29.28 P/Share
|
|
Feb 18
2025
|
Kathleen Skarvan Director |
SELL
Open market or private sale
|
Indirect |
5,000
-100.0%
|
$145,000
$29.15 P/Share
|
|
Feb 14
2025
|
Kathleen Skarvan Director |
SELL
Open market or private sale
|
Indirect |
23,989
-82.75%
|
$767,648
$32.07 P/Share
|
|
Feb 14
2025
|
Kathleen Skarvan Director |
SELL
Open market or private sale
|
Direct |
8,640
-5.46%
|
$276,480
$32.61 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 43.3K shares |
|---|---|
| Exercise of conversion of derivative security | 128K shares |
| Payment of exercise price or tax liability | 51.5K shares |
|---|---|
| Open market or private sale | 254K shares |